

AMENDMENTS

Listing of Claims

The following listing of claims replaces all previous listings or versions thereof:

- 1-17. (Canceled)
18. (Presently amended) An antibody or antibody fragment being low or not immunogenic in humans and recognizing the ~~native~~-human 17-1A antigen as expressed on the surface of cells, the ~~receptor~~antibody or antibody fragment being further characterized as comprising a human VH chain and a human VL chain wherein at least said VH chain is derived from unprimed mature human B-lymphocytes and said VL chain is derived from a naturally occurring human B cell repertoire.
19. (Presently amended) The antibody or antibody fragment according to claim 18, which is an antibody fragment~~-thereof~~.
- 20-21. (Canceled)
22. (Previously presented) The antibody or antibody fragment according to any one of claims 18, 19, 65, 66 or 67, wherein said VH comprises at least one CDR encoded by a portion of nucleotides 1 to 381 of Seq. ID NO: 143 and said VL chain comprises at least one CDR encoded by a portion of nucleotides 1 to 321 of Seq. ID No: 141.
- 23-27 (Canceled)
28. (Presently amended) An antibody or antibody fragment being characterized in that it comprises a human VH chain and a human VL chain, said ~~receptor~~antibody or antibody fragment recognizing the ~~native~~-human 17-1A antigen as expressed on the surface of cells.
29. (Previously presented) The antibody or antibody fragment of claim 28, said antibody or antibody fragment being low or not immunogenic in humans.

30. (Canceled)
31. (Previously presented) The antibody or antibody fragment of claim 28, recognizing an epitope of the extracellular domain of the 17-1A antigen.
32. (Previously presented) The antibody or antibody fragment of claim 28, wherein the VH chain comprises the amino acid sequence encoded by at least one of SEQ ID NOS: 143 and/or 145 and/or the VL chain comprises the amino acid sequence encoded by at least one of SEQ ID NOS:141 and/or 147.
- 33-37. (Canceled).
38. (Previously presented) A pharmaceutical composition comprising an antibody or antibody fragment according to claim 18, 65, 66 or 67, and a pharmaceutically acceptable carrier.
39. (Previously presented) A pharmaceutical composition comprising an according to claim 19, and a pharmaceutically acceptable carrier.
- 40-41. (Canceled)
42. (Previously presented) A pharmaceutical composition comprising an antibody or antibody fragment according to claim 22, and a pharmaceutically acceptable carrier.
- 43-52. (Canceled)
53. (Previously presented) A pharmaceutical composition comprising an antibody or antibody fragment according to claim 28, and a pharmaceutically acceptable carrier.
54. (Previously presented) A pharmaceutical composition comprising an antibody or antibody fragment according to claim 29, and a pharmaceutically acceptable carrier.
55. (Previously presented) A pharmaceutical composition comprising an antibody or antibody fragment according to claim 31, and a pharmaceutically acceptable carrier.

56. (Previously presented) A pharmaceutical composition comprising an antibody or antibody fragment according to claim 32, and a pharmaceutically acceptable carrier.

57-64. (Canceled)

65. (Previously presented) The antibody or antibody fragment according to claim 18, further comprising, fused to said human VH and VL chains, (a) the same or other VH or VL chains, (b) immunoglobulin constant regions of heavy (CH) or light chains (CL) or parts thereof, or (c) non-immunoglobulin chains, respectively.

66. (Previously presented) The antibody or antibody fragment according to claim 65, wherein said constant region chains are from human IgG1 or IgG3.

67. (Previously presented) The antibody or antibody fragment according to claim 18, further comprising linked to said human VH and VL chains a non-proteinous pharmaceutical and/or other biologically active molecule.